Social Media Discussion: $LLY

Eli Lilly's $2.75 billion deal with Insilico to develop AI-driven drugs signals a bullish sentiment towards innovation in pharmaceuticals. Meanwhile, a discussion on whether to sell individual stocks for S&P 500 exposure reflects a neutral stance on stock selection.